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Micro-pharmacokinetics: 
Quantifying local drug 
concentration at live cell 
membranes
Karolina Gherbi1,3, Stephen J. Briddon 1,2 & Steven J. Charlton  1,2,3
Fundamental equations for determining pharmacological parameters, such as the binding affinity of 
a ligand for its target receptor, assume a homogeneous distribution of ligand, with concentrations 
in the immediate vicinity of the receptor being the same as those in the bulk aqueous phase. It is, 
however, known that drugs are able to interact directly with the plasma membrane, potentially 
increasing local ligand concentrations around the receptor. We have previously reported an influence 
of ligand-phospholipid interactions on ligand binding kinetics at the β2-adrenoceptor, which resulted in 
distinct “micro-pharmacokinetic” ligand profiles. Here, we directly quantified the local concentration 
of BODIPY630/650-PEG8-S-propranolol (BY-propranolol), a fluorescent derivative of the classical 
β-blocker propranolol, at various distances above membranes of single living cells using fluorescence 
correlation spectroscopy. We show for the first time a significantly increased ligand concentration 
immediately adjacent to the cell membrane compared to the bulk aqueous phase. We further show a 
clear role of both the cell membrane and the β2-adrenoceptor in determining high local BY-propranolol 
concentrations at the cell surface. These data suggest that the true binding affinity of BY-propranolol 
for the β2-adrenoceptor is likely far lower than previously reported and highlights the critical importance 
of understanding the “micro-pharmacokinetic” profiles of ligands for membrane-associated proteins.
The fundamental equations routinely used in the determination of pharmacological parameters, such as binding 
affinities, assume a freely diffusible and homogeneously distributed ligand in solution. In experimental terms 
this means that the ligand concentration near the receptor is assumed to be the same as in the bulk aqueous 
phase. It is, however, known that drugs are able to interact directly with the plasma membrane1–5, and ligands 
that are able to partition into the lipid bilayer have been proposed to cause higher local ligand concentrations 
in the membrane1,2. Ligand diffusion in and out of these ligand depots in the membrane, and ligand interac-
tions at the membrane/water interface have also been proposed to potentially increase ligand concentrations 
in the immediate vicinity of the membrane compared to the bulk aqueous phase6, although ligand concentra-
tions in such defined localisations have never been experimentally measured before. We have recently reported a 
direct correlation of greater levels of ligand-phospholipid interactions and faster association rates for a range of 
β2-adrenoceptor ligands5, further suggesting the presence of higher local concentrations near the membrane due 
to the concentration-dependent nature of ligand association rates. The β-adrenoceptor antagonist propranolol has 
been shown to make hydrophobic and electrostatic interactions with phospholipid tails and head groups in the 
membrane7,8, although it is described to access the β2-adrenoceptor binding pocket from the aqueous solution 
above the extracellular surface of the receptor9.
In this study, we aimed to address this hypothesis of higher local drug concentrations, quantifying concentra-
tions of the fluorescent propranolol derivative BODIPY630/650-PEG8-S-propranolol (BY-propranolol)10 imme-
diately above the cell membrane and the bulk aqueous phase using fluorescence correlation spectroscopy (FCS). 
FCS measures fluorescence intensity fluctuations of a fluorescent species diffusing through a small (~0.25 fL) 
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confocal volume over time, with autocorrelation analysis of these fluctuations allowing quantification of the con-
centration and diffusion coefficient of the fluorescent species under investigation11. This single molecule detec-
tion technique has been used in highly localised subcellular compartments to gain spatiotemporal resolution of 
the dynamic interactions of fluorescently labelled molecules, such as lipids12, transcription factors13, cytoplas-
mic proteins14, membrane associated proteins15,16 and small molecule ligands17,18. Here we use FCS to show that 
BY-propranolol concentrations in the immediate vicinity of the membranes of individual CHO cells are substan-
tially higher than those in the bulk solution phase, and that these concentrations are influenced by the presence 
of the β2-adrenoceptor.
Results
Measuring local BY-propranolol concentrations above membranes of single cells. In order to 
determine ligand concentrations in the vicinity of individual cells, we used the technique of FCS. FCS uses a 
small defined detection volume of ~0.25 fL (0.2 × 1 μm) allowing a high spatial resolution to measurements of 
concentration. To investigate the distribution of drug concentration in the measurement well, we first measured 
BY-propranolol concentrations in solution in the absence of any cells at a range of distances from 3 µm to 207 µm 
above the glass coverslip (Fig. 1) to establish whether the measured concentration reflected the added concentra-
tion of 1.8 nM BY-propranolol (circa 1× KD; Extended Data Fig. 1) in these distinct locations. Autocorrelation 
analysis of BY-propranolol fluorescence fluctuations detected in the FCS detection volume placed 3, 4 and 5 µm 
above the coverslip revealed concentrations of 5.1 ± 0.8 nM (n = 8), 3.2 ± 0.4 nM (n = 8) and 3.3 ± 0.5 nM (n = 8), 
respectively, all of which were higher than the 1.8 nM BY-propranolol concentration added (P < 0.05, t-test). In 
contrast, concentrations at distances greater than 5 µm above the coverslip were not significantly different from 
the added concentration (P > 0.05, t-test), but showed a steady decline with increasing distance to 0.8 ± 0.1 nM 
(n = 8) measured 207 µm above the coverslip (Fig. 2a).
We next aimed to determine the BY-propranolol concentrations above membranes of cells from a stable mixed 
population of CHO-β2GFP cells that allowed the selection of non-receptor and receptor expressing cells based on 
the detection of GFP fluorescence (Extended Data Fig. 2). FCS measurements taken at 2 µm above the membrane 
of non-receptor expressing cells determined a BY-propranolol concentration of 19.2 ± 1.3 nM (n = 10), which was 
Figure 1. FCS experimental set-up used in this study. (a) Confocal image of receptor expressing (cell 1) 
and non-receptor expressing (cell 2) CHO-β2GFP cells, and control areas of no cell (area 3) used for FCS 
measurements. (b) Crosshair placement over the nucleus of a single cell was used to define the positioning 
of the FCS confocal volume in the x-y plane. (c) Detection of BY-propranolol fluorescence intensities in the z 
dimension allowed localisation of the upper cell membrane. (d) Schematic representation of confocal volume 
positions covering a range of distances from 2–200 µm above the upper membrane of a single cell in 1, 2, 10 
and 50 μm steps. (e) Determination of particle number (N) and dwell time (τD1) to quantify concentration and 
diffusion coefficient of BY-propranolol from its FCS autocorrelation curve.
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markedly higher than the concentration measured nearest the coverslip in the absence of cells (P < 0.05, two-way 
ANOVA). Furthermore, a steeper concentration gradient was observed, with ligand concentrations declining to 
1.5 ± 0.3 nM (n = 10) in the bulk aqueous phase 200 µm above cell membranes (Fig. 2a).
We then hypothesised that ligand concentrations near the membrane might be increased further in the pres-
ence of target receptors that facilitate specific ligand binding interactions6. To test this, we assessed BY-propranolol 
concentrations above membranes of cells with detectable β2GFP expression, as determined by GFP fluorescence 
intensity measurements (see Extended Data Fig. 2). Interestingly, the BY-propranolol concentration measured 
2 µm above the membrane of these cells was higher (45.7 ± 11.0 nM, n = 13) than the concentration obtained in 
cells without detectable receptor expression (P < 0.05, two-way ANOVA). To confirm that these findings were 
receptor-driven in a specific manner, we examined the effects of the β2-adrenoceptor selective antagonist ICI 
118,551 (550 nM, 10 min pre-incubation, 22 °C) on local BY-propranolol concentrations in the same cells. Indeed, 
ligand concentrations 2 µm above cell membranes were reduced in the presence of ICI 118,551 (27.1 ± 6.4 nM, 
n = 7). In cells with no detectable β2GFP expression BY-propranolol concentrations were unchanged in the pres-
ence of ICI 118,551 (Extended Data Fig. 3a). These data support the notion that the local BY-propranolol con-
centration in the immediate vicinity of the cell membrane is influenced by specific β2-adrenoceptor interactions. 
Whilst no direct ligand-receptor interactions were measured at a distance of 2 µm above the cell membrane, our 
data nevertheless highlight a receptor-driven component in the determination of local BY-propranolol concen-
trations that is blocked in the presence of an antagonist. Furthermore, BY-propranolol diffusion co-efficients 
were similar over all distances in all conditions tested in this study (Fig. 2b, Extended Data Fig. 3b), ruling out 
potential effects due to different diffusion characteristics near the membrane environment compared to the bulk 
aqueous phase.
Investigating local BY-propranolol concentration over time. To gain further insight into what 
might influence local drug concentrations, we examined BY-propranolol concentration at a fixed distance of 
2 µm above cell membranes over a time scale of 15 minutes to 2 hours, as all previously described experiments 
were performed following a 2 hour incubation of BY-propranolol. In the absence of cells, BY-propranolol con-
centrations measured closest to the coverslip did not change throughout the time course (Fig. 3), eliminating 
Figure 2. Role of the presence of the target receptor and the cell membrane on local BY-propranolol 
concentrations and diffusion coefficients. (a,b) Local concentrations (a) and diffusion coefficients (b) of BY-
propranolol measured 2–200 µm above membranes of receptor expressing (high) CHO-β2GFP cells in the 
absence (n = 13) and presence of 550 nM ICI 118,551 (ICI; n = 7) and non-receptor expressing (none) CHO-
β2GFP cells (n = 10) following 2 hours BY-propranolol incubation. The same experiments were carried out in 
areas of no cell (3–207 µm above the coverslip; absence of antagonist only; n = 8). Data shown are mean ± s.e.m. 
of n individual cells investigated on the same number of separate experimental days, and #denotes statistical 
significance (P < 0.05) of the value determined in receptor-expressing cells (CHO-β2GFP high) compared to 
the value determined in no cells, non-receptor expressing (CHO-β2GFP none) cells and receptor-expressing 
cells in the presence of ICI 118,551 at an equivalent distance from the coverslip (2-way ANOVA, Tukey’s post 
hoc test), whilst * Indicates statistically significant differences (P < 0.05) in ligand concentrations at various 
distances above the coverslip compared to the concentration determined at the furthest distance measured for 
each individual condition (2-way ANOVA, Tukey’s post hoc test). BY-propranolol diffusion coefficients were 
not statistically different across the range of distances tested (P > 0.05, 2-way ANOVA, Tukey’s post hoc test).
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the possibility of non-cell related artefacts over time. Measurements above membranes of cells of no detectable 
receptor expression revealed BY-propranolol concentration increases in a linear fashion over time, although the 
concentration differences observed at the different time points were not statistically significant (P > 0.05, two-way 
ANOVA). In contrast, above membranes of receptor expressing cells BY-propranolol concentrations were signifi-
cantly increased at 90 and 120 minutes compared to the first measurements taken at 15 and 30 minutes (P < 0.05, 
two-way ANOVA; Fig. 3a). This delay in increased local BY-propranolol concentrations may, at least in part, be 
related to its dissociation rate from the receptor (koff 0.04 min−1, t1/2 17 min; Extended Data Fig. 1b) and rebinding 
events whereby dissociated ligands bind neighbouring receptors instead of diffusing away into the bulk aqueous 
phase6,19, thus contributing to localising ligand concentrations near the membrane in a second order kinetic 
process19. In the same cells, in the presence of ICI 118, 551, BY-propranolol concentration increased in a similar 
pattern as detected in non-receptor expressing cells (Fig. 3a), confirming a receptor-driven influence on local 
ligand concentrations. The presence of ICI 118,551 did not affect BY-propranolol concentrations in cells with no 
detectable β2GFP expression (Extended Data Fig. 3c).
Discussion
Determination of accurate pharmacological parameters for a drug requires knowledge of the actual concentra-
tions of the given drug that the receptor and/or tissue is exposed to. Particularly for class A G protein-coupled 
receptors (GPCRs), the lipophilic nature of many of the ligands means that local membrane interactions, and 
potentially re-binding effects, could have a significant influence on the local drug concentrations and therefore 
influence the observed pharmacology. In this study, for the first time, we directly measure concentrations of a 
fluorescent β2-adrenergic receptor ligand, BY-propranolol, in the immediate vicinity of a cell monolayer. Not only 
is the drug present in higher concentrations in the near vicinity of the cell membrane, but this is amplified further 
by the presence of the β2-adrenoceptor.
In this study we used a BY-propranolol concentration reflecting its affinity (1.8 nM; 1 × KD) determined 
from equilibrium and kinetic binding calculations that assume a homogeneous distribution of ligand in the 
assay volume. However, our data have clearly shown that this assumption does not hold true and that the actual 
BY-propranolol concentrations the target receptors are exposed to are in fact much higher than the added con-
centration. Using the BY-propranolol concentration measured nearest the cell membrane in the microenviron-
ment of the receptor (Fig. 4) yields a 25-fold lower (i.e. 45 nM) “true affinity” of BY-propranolol. Importantly, 
this concentration might possibly still be higher directly above the extracellular space of the receptors. We have 
recently estimated between 4 and 3,000-fold lower “true affinity” values for a range of β2-adrenoceptor ligands5, 
although these were based on their membrane partition coefficients (logKIAM), which reflect direct ligand inter-
actions with membrane phospholipids.
It is interesting to consider what the ligand concentrations in the cell membrane might be, although these are 
technically challenging to determine using FCS due to differences in molecular brightness of BODIPY-labelled 
fluorescent ligands in aqueous compared to membrane environments20 and limitations of the FCS dynamic 
detection range for high ligand concentrations11. With these limitations in mind we have attempted to esti-
mate ligand concentrations within the membrane, and our calculations suggest a time-dependent increase in 
BY-propranolol concentrations in the cell membrane of both receptor expressing and non-receptor expressing 
cells (Extended Data Fig. 4), with concentrations of 734 ± 137 nM (n = 9) and 835 ± 127 nM (n = 6) after 2 hours, 
respectively. These much higher membrane concentrations of ligand could potentially contribute further to the 
micro-pharmacokinetic profile of ligands that access their receptors via lateral diffusion in the membrane2,21,22, 
Figure 3. Effect of incubation time on BY-propranolol concentrations in the immediate vicinity of cell 
membranes. Local concentrations of BY-propranolol 2 µm above membranes of receptor expressing (high) 
CHO-β2GFP cells in the absence (n = 13) and presence of 550 nM ICI 118,551 (ICI; n = 7) and non-receptor 
expressing (none) CHO-β2GFP cells (n = 10) following a 15, 30, 60, 90 and 120 minutes BY-propranolol 
incubation. The same experiments were carried out in areas of no cell (data from measurements 3 µm above the 
coverslip; absence of antagonist only; n = 8). Data shown are mean ± s.e.m. of n individual cells investigated 
on the same number of separate experimental days, and #denotes statistical significance (P < 0.05) of the value 
determined in receptor-expressing cells (CHO-β2GFP high) compared to the value determined in no cells at 
an equivalent time point (2-way ANOVA, Tukey’s post hoc test). *Indicates statistically significant differences 
(P < 0.05) in ligand concentrations compared to the concentration determined at the 15 minute time point (2-
way ANOVA, Tukey’s post hoc test).
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but are unlikely to be directly available to bind the β2-adrenoceptor as β-adrenoceptor ligands have been proposed 
to access their target receptor via its extracellular space in the aqueous solution9. It is therefore more likely that 
β-adrenoceptor ligands feed into the aqueous solution from a membrane sink, a mechanism that has previously 
been described in the ‘diffusion microkinetic model’23, and provides one possible explanation for the increas-
ing concentrations observed over time at 2 µm above membranes of both receptor expressing and non-receptor 
expressing cells.
Interestingly however, BY-propranolol concentrations increased significantly over time only above mem-
branes of receptor expressing cells, further supporting the role of the target receptor in concentrating ligand 
around its extracellular space. The influence of the receptor on local ligand concentration becomes an important 
notion, especially when considering different receptor expression levels not only in different tissues24 and cells25, 
but also in microdomains of a single cell26,27. It is widely appreciated that receptors are not uniformly distributed 
in cell membranes, and that they are associated with different effector and scaffolding proteins in different micro-
domains26,28, creating micro-environments of different potential ligand interactions. Our findings suggest that the 
presence and magnitude of a ligand concentration gradient may be influenced by the level and types of possible 
ligand interactions, which will depend on the physicochemical properties5 (e.g. charge, lipophilicity) of the ligand 
as well as the composition of the surface. Ligand interactions with membrane components such as phospholipids 
and sphingolipids have been described4,7,8,21,29, and provide additional interactions compared to those available in 
the bulk aqueous phase driving an increased local ligand concentration. Multicellular environments in vitro and 
in vivo will provide a much more complex level of ligand interactions resulting in unique micro-pharmacokinetic 
profiles for each ligand-receptor-cell micro-environment that may contribute to tissue-specific pharmacology for 
a given ligand-receptor complex.
As such, there is a clear need to develop approaches that allow better understanding of a ligand’s 
micro-pharmacokinetic profile and estimation of its local concentrations in a given micro-environment. 
Incorporation of these properties into current analyses of pharmacological characteristics has the potential 
to allow more accurate and therefore more physiologically relevant assessment of mechanisms of actions of 
ligands, and to drive drug design and optimisation strategies in early stages of drug discovery programs. For 
example, increased ligand-membrane interactions are thought to contribute to the long duration of action of 
β2-adrenoceptor agonists23,30 and may present a desirable feature in the design of new inhaled drugs. Furthermore, 
targeted drug design that takes into account ligand interactions in the multicellular environment of the target tis-
sue may optimise tissue-specific pharmacology, maximising therapeutic effects and minimising unwanted side 
effects.
Methods
Cell culture. CHO-K1 cells (negative in PCR-based mycoplasma test) were stably transfected with cDNA 
encoding the human wild-type β2-adrenoceptor C-terminally tagged with the green fluorescent protein (GFP) to 
generate a mixed population CHO-β2GFP cell line (DNA sequencing verified the receptor sequence). Transfection 
was achieved using Lipofectamine (Life Technologies) according to the manufacturer’s instruction, and subsequent 
selective pressure (1 mg/mL G418) for 2–3 weeks. Following this, CHO-β2GFP cells were grown at 37 °C in CHO 
growth medium (phenol-red free Dulbecco’s modified Eagle’s medium/nutrient mixture F12 (Sigma-Aldrich) con-
taining 10% (v/v) fetal bovine serum and 2 mM L-glutamine) in a humidified 5% CO2/95% air atmosphere.
BODIPY630/650-PEG8-S-propranolol binding studies. BODIPY630/650-PEG8-S-propranolol 
(Compound 18a, ref.10) binding properties were determined in time-resolved Förster resonance energy 
transfer (TR-FRET) experiments using the Tag-lite® technology (Cisbio Bioassays). For saturation binding 
Figure 4. Schematic representation of increased local ligand concentrations in the immediate vicinity of the 
cell membrane and target receptors compared to the bulk aqueous phase. A ligand concentration gradient may 
potentially be caused by ligand interactions with both cell membrane components and target receptors (R). To 
account for heterogeneous ligand distribution in the determination of pharmacological parameters, higher local 
ligand concentrations (Lmicro) may be used, as shown here for affinity (Kd) calculations.
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assays, membranes of HEK293 cells containing Lumi4®-Terbium labelled SNAP-tagged β2-adrenoceptors 
(HEK-ssβ2LT; 1 µg per well) were incubated in 384-well OptiPlates (PerkinElmer) at room temperature in 
binding assay buffer (Tag-lite® assay buffer (Cisbio Bioassays), 0.1% (v/v) pluronic acid, 100 µM GTPγS) 
with a range of BODIPY630/650-PEG8-S-propranolol concentrations (0.001–300 nM) in the absence and 
presence of 10 µM ICI 118,551 for 2 hours with gentle agitation, to determine total and non-specific bind-
ing, respectively. In kinetic binding experiments, observed association rates (konob) of four increasing 
BODIPY630/650-PEG8-S-propranolol concentrations were obtained to allow accurate determination of 
association (kon) and dissociation rates (koff). BODIPY630/650-PEG8-S-propranolol concentrations were 
incubated in 384-well OptiPlates (room temperature) in binding assay buffer in the absence (total binding) 
and presence (non-specific binding) of 10 µM ICI 118,551. Kinetic reactions were started by the addition of 
HEK-ssβ2LT membranes (1 µg per well), and binding levels were measured every 30 seconds for 1 hour. The 
PHERAstar® FS plate reader (BMG Labtech) was used to measure fluorescence intensity emissions at 620 nm 
(HEK-ssβ2LT) and 665 nm (BODIPY630/650-PEG8-S-propranolol) following excitation (3 flashes per well) 
of Lumi4®-Terbium labelled SNAP-tagged β2-adrenoceptors at 337 nm using a Homogeneous Time-Resolved 
Fluorescence (HTRF) module. A TR-FRET ratio of 665 nm/620 nm fluorescence emissions (multiplied by 
10,000) was calculated, and non-specific binding was subtracted from total binding to determine specific 
BODIPY630/650-PEG8-S-propranolol binding levels.
Fluorescence correlation spectroscopy (FCS). CHO-β2GFP cells were seeded into 8-well Labtek borosil-
icate chambered-cover glass plates (Nalgene Nunc International, Fisher Scientific) two days prior to experimenta-
tion, and grown to 50% confluency in CHO growth medium. On the day of the experiment, cells were equilibrated 
at 22 °C in HEPES buffered saline (HBS)31, and then exposed to 1.8 nM BODIPY630/650-PEG8-S-propranolol, 
before FCS measurements were performed on a Zeiss LSM510NLO Confocor 3 confocal microscope (Carl Zeiss, 
Jena) using a 40 × 1.2NA water immersion objective lens at 22 °C. The FCS measurement volume for the beam-
path used in these experiments was calibrated using 10 × 10 s data collection of a 10 nM Cy5-NHS ester solution 
on each experimental day31. For cell measurements, the confocal volume was positioned in x-y over a single 
CHO-β2GFP cell using a confocal image of GFP fluorescence (488 nm excitation, BP505/560 nm emission). 
Subsequent z-scanning was performed using ~0.03 kW/cm2 633 nm helium-neon excitation to allow positioning 
of the confocal volume 2 µm above the peak fluorescent intensity of the upper cell membrane. FCS measurements 
of 30 seconds with ~2.4 kw/cm2 633 nm excitation (LP650 nm emission) were taken 2–200 µm above the upper 
cell membrane, moving upwards in 1, 2, 10 and 50 µm increments as determined by the microscope harmonic 
drive within Zeiss AIM 3.5 software, following 15, 30, 60, 90 and 120 min BODIPY630/650-PEG8-S-propranolol 
incubation at 22 °C. In control areas of no cells FCS measurements were taken every 1 µm from 3–7 µm above 
coverslip (reaching equivalent average height of upper cell membranes), before following the same increments 
and distances measured in cell experiments. In antagonist experiments, cells were pre-incubated with 550 nM ICI 
118,551 for 10 min (22 °C) prior to BODIPY630/650-PEG8-S-propranolol addition. Confocal imaging and FCS 
measurement settings were kept constant for all experiments.
Data analysis and statistical procedures. Using Prism 6.0 (GraphPad Software) BODIPY630/650- 
PEG8-S-propranolol saturation binding data were analysed and association data were globally fitted as previously 
described32.
FCS analysis and data fitting was performed using Zen2010 software (Carl Zeiss, Jena). The measure-
ment volume was calculated for each separate experiment using the measured dwell time (τD) and structure 
parameter values from the Cy5-NHS ester solution calibration measurements, along with its literature dif-
fusion coefficient (D = 3.16 × 10−10 m2/s) as previously described31. BODIPY630/650-PEG8-S-propranolol 
autocorrelation curves obtained from measurements in aqueous solution were fitted to a simple model 
describing one freely diffusing 3D diffusion component. For measurements within the cell membrane envi-
ronment a model was used with one 3D diffusion component (free ligand) and one or two 2D diffusion 
components, as necessary (membrane bound ligand). For these fits, the dwell time of the 3D component 
was fixed to that of BODIPY630/650-PEG8-S-propanolol determined in aqueous solution experiments per-
formed on the same day (τD ~ 140 µs). To correct particle number values in membrane reads for differ-
ences in the BODIPY630/650-PEG8-S-propranolol quantum yield in aqueous solution compared to the 
membrane, molecular brightness values were determined in these two environments by performing photon 
counting histogram analysis in an aqueous solution of BODIPY630/650-PEG8-S-propranolol (10 µm above 
membrane, component 1) and on the upper cell membrane (component 2) following 15 min incubation 
with 10 nM BODIPY630/650-PEG8-S-propranolol (1 × 60 s read, 1.0 kW/cm2 laser power), and a bright-
ness correction ratio of 9.1 (component 2/component 1) was defined. BODIPY630/650-PEG8-S-propranolol 
concentrations and diffusion coefficients were determined using the calculated confocal volume from FCS 
calibration measurements for that day’s experiment. The confocal volume positioned at the cell membrane 
spans the membrane encompassing intra- and extracellular spaces in addition to the membrane. Ligand 
concentrations in the membrane were estimated from the particle number of the membrane component 2 
in the autocorrelation fit of membrane measurements, and an estimated volume of a cylinder with an area 
of the FCS volume beam waist and the height of the membrane bilayer (5 nm). FCS measurements on one 
single cell per experimental condition were performed on one experimental day and as such represent one 
n number in this study.
Statistical analysis was performed on mean ± s.e.m. data using Graphpad Prism 6.0, with P < 0.05 represent-
ing statistical significance. T-test analysis was used to compare ligand concentrations to a fixed value (1.8 nM of 
BY-propranolol used in experiments), two-way ANOVA followed by Dunnett’s multiple comparison test was used 
to compare ligand concentrations from a range of distances above the cell membrane to the ligand concentration 
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in the bulk aqueous phase (200 µm above membrane), and two-way ANOVA followed by Tukey’s multiple com-
parison test was used to compare ligand concentrations obtained under different experimental conditions for 
each distance.
Data availability. All data supporting the findings of this study are available from the corresponding author 
on request.
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